Skip to main content
. Author manuscript; available in PMC: 2014 Jan 2.
Published in final edited form as: Curr Cancer Drug Targets. 2013 May;13(4):411–422. doi: 10.2174/1568009611313040005

Figure 2. Effect of MS-275 on caspase activity in OS cells.

Figure 2

Figure 2

LM7 and CCH-OS-D cells were treated with 2 μM MS-275 for 48 hours with or without 10 ng/ml sFasL for 24 hours. Cell lysates were separated by 10% SDS-PAGE. (A) Immunoblot analysis was done using an antibody against pro-caspase-8. Numbers represent densitometry changes relative to β-actin and compared to the untreated sample. (B) Caspase-8 and (C) caspase-3 activity assays following treatment. *P-values are compared to control and either agent alone. (D) LM7 and CCH-OS-D cells were pretreated with 20 μM Z-VAD-fmk for 2 hours followed by treatment with 2 μM MS-275 for 48 hours with or without sFasL for 24 hours. MTT assay was performed to assess cytotoxicity. *p < 0.02, n=3.